Case reports have suggested that the use of newer cyclo-oxygenase-2 (COX-2) selective inhibitors may cause acute pancreatitis.
There has, however, not been a formal study of the association.
Dr Sorensen and colleagues assessed the relationship between the use of cyclo-oxygenase-2 inhibitors and other non-steroidal anti-inflammatory drugs, and risk of acute pancreatitis.
The doctors conducted a population-based case-control study using hospital discharge and prescription data from Denmark.
The team used conditional logistic regression with adjustment for multiple covariates.
|The relative risk for celecoxib was 1.4 vs 2.7 for other non-steroidal anti-inflammatory drugs|
|Alimentary Pharmacology & Therapeutics|
The relative risk for use of the cyclo-oxygenase-2 inhibitors celecoxib, rofecoxib, and for other non-steroidal anti-inflammatory drugs was assessed.
The doctors identified a total of 3083 cases of acute pancreatitis and 30,830 population controls.
For current use, the relative risk estimate for celecoxib was 1.4, and 1.3 for rofecoxib.
The overall relative risk for other non-steroidal anti-inflammatory drugs was 2.7.
However, the team noted substantial variation in risk between the individual drugs.
The highest relative risk was for diclofenac, and the lowest for naproxen.
Dr Sorensen's team concluded, “Cyclo-oxygenase-2 selective inhibitors are associated with a lower risk of acute pancreatitis than most other non-steroidal anti-inflammatory drugs.”